EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Beta 2a

Ensembl ID : ENSNFUG00015008959
Gene Symbol: ATP1B2A
1 Cross references
200 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSNFUG00015016200
Gene Symbol: ATP1B3
3 Cross references
236 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSNFUG00015011765
Gene Symbol: AXL
1 Cross references
187 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSNFUG00015003031
Gene Symbol: BRAF
3 Cross references
219 Possible Orthologues:

B2 Bradykinin Receptor-Like

Ensembl ID : ENSNFUG00015024170
Gene Symbol: LOC107392056
3 Cross references
147 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSNFUG00015007577
Gene Symbol: BCL2
3 Cross references
176 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSNFUG00015007912
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSNFUG00015009084
Gene Symbol: LOC107383715
3 Cross references
188 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSNFUG00015013060
Gene Symbol: CCR9
3 Cross references
193 Possible Orthologues:

C-X-C Chemokine Receptor Type 1-Like

Ensembl ID : ENSNFUG00015006347
Gene Symbol: LOC107389382
3 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSNFUG00015023775
Gene Symbol: CXCR4
3 Cross references
201 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSNFUG00015017418
Gene Symbol: LOC107379659
3 Cross references
408 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).